Wall Street analysts expect that Sangamo Therapeutics Inc (NASDAQ:SGMO) will report earnings per share (EPS) of ($0.05) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Sangamo Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.20) and the highest estimate coming in at $0.26. Sangamo Therapeutics reported earnings per share of ($0.23) in the same quarter last year, which suggests a positive year-over-year growth rate of 78.3%. The company is scheduled to announce its next earnings results on Wednesday, May 9th.
According to Zacks, analysts expect that Sangamo Therapeutics will report full year earnings of ($0.15) per share for the current financial year, with EPS estimates ranging from ($0.89) to $0.45. For the next financial year, analysts expect that the business will report earnings of ($0.62) per share, with EPS estimates ranging from ($1.49) to $0.04. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.03. Sangamo Therapeutics had a negative return on equity of 31.44% and a negative net margin of 149.23%. The firm had revenue of $13.08 million for the quarter, compared to analysts’ expectations of $11.10 million. During the same period last year, the business posted ($0.14) earnings per share. The firm’s revenue for the quarter was up 46.6% on a year-over-year basis.
A number of research firms have issued reports on SGMO. BidaskClub upgraded Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 17th. Jefferies Group reiterated a “buy” rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. Wedbush reiterated a “hold” rating and issued a $8.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, March 13th. Piper Jaffray Companies set a $25.00 target price on Sangamo Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Finally, Zacks Investment Research cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $20.83.
Sangamo Therapeutics (NASDAQ:SGMO) opened at $23.10 on Tuesday. Sangamo Therapeutics has a one year low of $3.85 and a one year high of $27.50. The stock has a market capitalization of $2,028.97, a price-to-earnings ratio of -33.00 and a beta of 2.60. The company has a debt-to-equity ratio of 0.13, a quick ratio of 5.54 and a current ratio of 5.54.
In other news, Director Steven J. Mento sold 9,433 shares of the firm’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $23.27, for a total transaction of $219,505.91. Following the transaction, the director now directly owns 8,480 shares of the company’s stock, valued at $197,329.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kathy Yi sold 5,000 shares of the firm’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $25.56, for a total value of $127,800.00. Following the transaction, the chief financial officer now directly owns 12,250 shares in the company, valued at $313,110. The disclosure for this sale can be found here. Insiders sold 95,403 shares of company stock worth $2,035,169 over the last quarter. 5.50% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of SGMO. Alexandria Capital LLC acquired a new position in shares of Sangamo Therapeutics during the fourth quarter valued at $15,179,000. State Street Corp increased its holdings in shares of Sangamo Therapeutics by 51.6% during the second quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock valued at $16,441,000 after purchasing an additional 636,296 shares during the period. American Century Companies Inc. acquired a new position in shares of Sangamo Therapeutics during the third quarter valued at $5,145,000. Tocqueville Asset Management L.P. increased its holdings in shares of Sangamo Therapeutics by 105.0% during the fourth quarter. Tocqueville Asset Management L.P. now owns 665,890 shares of the biopharmaceutical company’s stock valued at $10,921,000 after purchasing an additional 341,075 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Sangamo Therapeutics by 58.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 911,512 shares of the biopharmaceutical company’s stock valued at $14,948,000 after purchasing an additional 336,107 shares during the period. 64.68% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Sangamo Therapeutics Inc (SGMO) Expected to Announce Earnings of -$0.05 Per Share” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.thelincolnianonline.com/2018/03/20/sangamo-therapeutics-inc-sgmo-expected-to-announce-earnings-of-0-05-per-share.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.